DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol

Information source: Ajou University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Blood Pressure; Ischemic Stroke

Intervention: Fimasartan (Drug); Valsartan (Drug); Atenolol (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Ajou University School of Medicine

Summary

Confirm central blood pressure reduction effect of Fimasartan, Valsartan and Atenolol and compare correlation with the measured peripheral (central blood pressure, pulse wave velocity, and flow-mediated dilation) and cerebral blood flow factors (transcranial doppler findings, cerebral blood flow volume) in acute ischemic stroke patients with hypertension.

Clinical Details

Official title: Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Central Blood pressure control

Secondary outcome:

Blood pressure at the brachial artery

Brachial-ankle pulse wave velocity (ba-PWV)

Flow-mediated dilation (FMD)

Pulsatile index (PI)

Cerebral blood flow (CBF) volume

Adverse Events

Eligibility

Minimum age: 30 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age ≥ 30 years old

- Acute ischemic stroke patient who has corresponding DWI(diffusion- weighted

imaging) lesion correlated with symptom

- after 7days, but within 28days from stroke onset

- Diagnosed with Hypertension

- hypertensive patients who taking anti-hypertensive drugs or SBP≥140mmHg

- Informed consent

Exclusion Criteria:

- Patients with hemorrhagic Stroke

- Patients with severe Stroke - over NIHss(National Institutes of Health stroke scale)

16

- Uncontrolled hypertension (SBP ≥200mmHg)

- Patients with history of allergic reaction to any angiotensin II antagonist

- Liver disease(more than double to normal level, SGOT(serum glutamic-oxaloacetic

transaminase ), SGPT(serum glutamic-pyruvic transaminase ), total bilirubin)

- Renal disease(serum creatinine ≥2. 0mg/dl)

- Anemia(Hb < 8mg/dl)

- Thrombocytopenia( < 10^3/ml)

- Patients with secondary hypertension

- Childbearing and breast-feeding women

- Otherwise inappropriate patients depending on the investigator's decision

Locations and Contacts

Additional Information

Starting date: May 2012
Last updated: March 26, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017